Drugs & TargetsFree FDA accepts Astellas’s sNDA for Cresemba in children August 11, 2023Vol.49 No.32
Drugs & Targets FDA approves Jemperli with chemotherapy for endometrial cancer August 04, 2023Vol.49 No.31
Drugs & Targets FDA approves Lonsurf with bevacizumab for previously treated metastatic colorectal cancer August 04, 2023Vol.49 No.31
In Brief Patient Engagement Collaborative calls for applications for members July 21, 2023Vol.49 No.29
Drugs & Targets FDA grants Ambrx Fast Track designation for prostate cancer ADC therapy July 21, 2023Vol.49 No.29
Can ctDNA be used as an endpoint for cancer drug development?Friends collaboration to present initial results July 11 July 07, 2023Vol.49 No.27By Matthew Bin Han Ong
Drugs & Targets FDA establishes Oncology Quality, Characterization and Assessment of Real-World Data Initiative June 30, 2023Vol.49 No.26
In the era of immunotherapy and targeted therapies, ODAC focuses on dose optimization in children June 23, 2023Vol.49 No.25By Jacquelyn Cobb
Drugs & Targets FDA approves Talzenna with enzalutamide for HRR gene-mutated metastatic castration-resistant prostate cancer June 23, 2023Vol.49 No.25
